Aberdeen Wealth Management LLC trimmed its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 64.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,542 shares of the medical research company's stock after selling 2,807 shares during the period. Aberdeen Wealth Management LLC's holdings in Amgen were worth $558,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in AMGN. Dogwood Wealth Management LLC grew its position in Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company's stock worth $25,000 after buying an additional 55 shares in the last quarter. Anfield Capital Management LLC raised its holdings in Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company's stock valued at $25,000 after acquiring an additional 70 shares in the last quarter. Tower View Wealth Management LLC raised its holdings in Amgen by 331.6% in the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company's stock valued at $29,000 after acquiring an additional 63 shares in the last quarter. Manning & Napier Advisors LLC lifted its position in shares of Amgen by 49.2% in the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company's stock worth $32,000 after acquiring an additional 32 shares during the period. Finally, Ares Financial Consulting LLC bought a new stake in shares of Amgen in the 4th quarter worth approximately $34,000. Institutional investors own 76.50% of the company's stock.
Wall Street Analyst Weigh In
A number of equities analysts have recently issued reports on the stock. Guggenheim increased their price objective on shares of Amgen from $343.00 to $388.00 and gave the company a "neutral" rating in a research note on Monday, August 10th. Wall Street Zen raised shares of Amgen from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th. Daiwa Securities Group decreased their price objective on Amgen from $410.00 to $390.00 and set an "outperform" rating on the stock in a report on Wednesday, May 13th. Canaccord Genuity Group increased their target price on Amgen from $366.00 to $384.00 and gave the stock a "hold" rating in a report on Wednesday, August 5th. Finally, Sanford C. Bernstein raised their target price on Amgen from $335.00 to $345.00 and gave the stock a "market perform" rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, Amgen has a consensus rating of "Hold" and an average target price of $380.43.
Check Out Our Latest Analysis on AMGN
Insider Transactions at Amgen
In related news, SVP Rachna Khosla sold 2,000 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00. Following the completion of the sale, the senior vice president directly owned 6,404 shares of the company's stock, valued at $2,642,098.28. The trade was a 23.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Nancy A. Grygiel sold 2,970 shares of the company's stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president owned 7,340 shares of the company's stock, valued at $2,951,854.40. The trade was a 28.81% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 6,222 shares of company stock worth $2,540,926. Corporate insiders own 0.85% of the company's stock.
Amgen Price Performance
Shares of AMGN stock opened at $443.84 on Tuesday. Amgen Inc. has a 1 year low of $269.77 and a 1 year high of $445.87. The firm's 50 day moving average is $380.90 and its 200-day moving average is $362.81. The firm has a market capitalization of $239.95 billion, a price-to-earnings ratio of 27.58, a PEG ratio of 3.17 and a beta of 0.41. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44.
Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating analysts' consensus estimates of $5.62 by $0.67. The business had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. Amgen's revenue for the quarter was up 9.5% compared to the same quarter last year. During the same quarter last year, the business posted $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Sell-side analysts forecast that Amgen Inc. will post 22.92 EPS for the current fiscal year.
Amgen Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend is Friday, August 21st. Amgen's payout ratio is currently 62.65%.
Amgen Profile
(
Free Report)
Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.
Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
